Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients
Public ClinicalTrials.gov record NCT00110266. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open Label, Safety and Tolerability Study of Deferasirox for Treatment of Transfusional Iron Overload in Low-risk and INT-1, Myelodysplastic Patients Using Serum Ferritin Monitoring
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this trial is to examine the safety and efficacy of deferasirox in patients with Myelodysplastic Syndrome (MDS) and chronic iron overload from blood transfusions.
Study identification
- NCT ID
- NCT00110266
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 176 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 24, 2005
- Primary completion
- Mar 27, 2008
- Completion
- Mar 27, 2008
- Last update posted
- Aug 15, 2021
2005 – 2008
United States locations
- U.S. sites
- 42
- U.S. states
- 31
- U.S. cities
- 39
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Univ of Alabama Birmingham | Birmingham | Alabama | 35294 | — |
| Mayo Clinic | Phoenix | Arizona | 85054 | — |
| Bay Area Cancer Research Group | Concord | California | 94520 | — |
| City of Hope National Medical Center | Duarte | California | 91010 | — |
| Cedars-Sinai Medical Center, UCLA School of Medicine | Los Angeles | California | 90048 | — |
| UCLA Medical Center | Los Angeles | California | 90095-1678 | — |
| UCSF | San Francisco | California | 94143-0324 | — |
| UCSF | San Francisco | California | 94143 | — |
| Rocky Mountain Cancer Centers | Aurora | Colorado | 80012 | — |
| Mayo Clinic | Jacksonville | Florida | 32224 | — |
| Emory University School of Medicine/Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| Straub Clinic and Hospital | Honolulu | Hawaii | 96813 | — |
| Novartis Investigative Site | Chicago | Illinois | 60612 | — |
| University of Chicago Hospital | Chicago | Illinois | 60637-1470 | — |
| University of Kansas Medical Center | Kansas City | Kansas | 66160 | — |
| University of Kentucky College of Medicine, Markey Cancer Center | Lexington | Kentucky | 40536-0093 | — |
| Cabrini Center for Cancer Care/Christus St. Frances Cabrini Hospital | Alexandria | Louisiana | 71301 | — |
| St. Agnes HealthCare | Baltimore | Maryland | 21231-1000 | — |
| Rush Cancer Institute Univ. of Massachussets Medical Center | Worcester | Massachusetts | 01605 | — |
| Novartis Investigative Site | Southfield | Michigan | 48075 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| The Center for Cancer Care & Research (TCCCR) | St Louis | Missouri | 63110 | — |
| Oncology Hematology West, PC | Omaha | Nebraska | 68124-2346 | — |
| Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire | 03756-0001 | — |
| The Cancer Center at Hackensack University | Hackensack | New Jersey | 07601 | — |
| NMOHC | Albuquerque | New Mexico | 87109 | — |
| Roswell Park Cancer Center | Buffalo | New York | 14623 | — |
| Rochester General Hospital/Lipson Cancer and Blood Center | Rochester | New York | 14621 | — |
| Cancer Care of WNC | Asheville | North Carolina | 28801 | — |
| Wake Forest UniversitComprehensive Cancer Center | Winston-Salem | North Carolina | 27157-1082 | — |
| The Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| The Ohio State University | Columbus | Ohio | 43210 | — |
| Novartis Investigative Site | Portland | Oregon | 97239 | — |
| Thomas Jefferson University; Jefferson Medical College, Kimmel Cancer Center | Philadelphia | Pennsylvania | 19107 | — |
| Western Pennsylvania Hospital Cancer Institute | Pittsburgh | Pennsylvania | 15224 | — |
| The West Cancer Clinic | Memphis | Tennessee | 38120 | — |
| Novartis Investigative site | Nashville | Tennessee | 37232 | — |
| Baylor/The Methodist Hospital | Houston | Texas | 77030 | — |
| Utah Cancer Specialists | Salt Lake City | Utah | 84106 | — |
| Arlington Fairfax Hematology Oncology PC | Arlington | Virginia | 22205 | — |
| Novartis Investigative Site | Spokane | Washington | 99202 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00110266, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 15, 2021 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00110266 live on ClinicalTrials.gov.